Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $22,616 | 8 | 100.0% |
| Food and Beverage | $11.13 | 1 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Servier BioInnovation | $22,616 | 8 | $0 (2024) |
| Philips Electronics North America Corporation | $11.13 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $562.82 | 2 | Servier BioInnovation ($562.82) |
| 2023 | $22,053 | 6 | Servier BioInnovation ($22,053) |
| 2018 | $11.13 | 1 | Philips Electronics North America Corporation ($11.13) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/14/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $287.19 | Research |
| Study: Survival with guideline-concordant pediatric-inspired regimens for acute lymphoblastic leukemia in adolescents/young adults: a real-world study | ||||||
| 06/20/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $275.63 | Research |
| Study: Survival with guideline-concordant pediatric-inspired regimens for acute lymphoblastic leukemia in adolescents/young adults: a real-world study | ||||||
| 12/26/2023 | Servier BioInnovation | — | — | Cash or cash equivalent | $1,891.67 | Research |
| Study: Patterns of care among adolescents and young adults treated for acute lymphoblastic leukemia: A retrospective study across diverse US practices | ||||||
| 10/28/2023 | Servier BioInnovation | — | — | Cash or cash equivalent | $8,816.67 | Research |
| Study: Patterns of care among adolescents and young adults treated for acute lymphoblastic leukemia: A retrospective study across diverse US practices | ||||||
| 10/03/2023 | Servier BioInnovation | — | — | Cash or cash equivalent | $2,061.11 | Research |
| Study: Comparison of Overall Survival Among Adolescents and Young Adults (AYA) with Newly-diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with Pediatric-inspired or Non-pediatric Inspired Regimens: A Real-World Analysis Using Claims Data | ||||||
| 08/25/2023 | Servier BioInnovation | — | — | Cash or cash equivalent | $1,236.67 | Research |
| Study: Comparison of Overall Survival Among Adolescents and Young Adults (AYA) with Newly-diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with Pediatric-inspired or Non-pediatric Inspired Regimens: A Real-World Analysis Using Claims Data | ||||||
| 08/17/2023 | Servier BioInnovation | — | — | Cash or cash equivalent | $7,222.22 | Research |
| Study: Patterns of care among adolescents and young adults treated for acute lymphoblastic leukemia: A retrospective study across diverse US practices | ||||||
| 07/31/2023 | Servier BioInnovation | — | — | Cash or cash equivalent | $824.44 | Research |
| Study: Comparison of Overall Survival Among Adolescents and Young Adults (AYA) with Newly-diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with Pediatric-inspired or Non-pediatric Inspired Regimens: A Real-World Analysis Using Claims Data | ||||||
| 01/15/2018 | Philips Electronics North America Corporation | Respiratoriy Care Undiv (Device) | Food and Beverage | Cash or cash equivalent | $11.13 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Patterns of care among adolescents and young adults treated for acute lymphoblastic leukemia: A retrospective study across diverse US practices | Servier BioInnovation | $17,931 | 3 |
| Comparison of Overall Survival Among Adolescents and Young Adults (AYA) with Newly-diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with Pediatric-inspired or Non-pediatric Inspired Regimens: A Real-World Analysis Using Claims Data | Servier BioInnovation | $4,122 | 3 |
| Survival with guideline-concordant pediatric-inspired regimens for acute lymphoblastic leukemia in adolescents/young adults: a real-world study | Servier BioInnovation | $562.82 | 2 |
About Dr. Michael Roth, M.D
Dr. Michael Roth, M.D is a Pediatric Hematology-Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2009. The National Provider Identifier (NPI) number assigned to this provider is 1790915254.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Roth, M.D has received a total of $22,627 in payments from pharmaceutical and medical device companies, with $562.82 received in 2024. These payments were reported across 9 transactions from 2 companies. The most common payment nature is "" ($22,616).
Practice Information
- Specialty Pediatric Hematology-Oncology
- Location Houston, TX
- Active Since 07/19/2009
- Last Updated 07/25/2017
- Taxonomy Code 2080P0207X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1790915254
Products in Payments
- Respiratoriy Care Undiv (Device) $11.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Houston
Vivek Subbiah, Md, MD
Pediatric Hematology-Oncology — Payments: $184,004
Helen Heslop, Md, MD
Pediatric Hematology-Oncology — Payments: $73,908
Dr. Jenny Despotovic, D.o, D.O
Pediatric Hematology-Oncology — Payments: $71,551
Jennifer Foster, Md, MD
Pediatric Hematology-Oncology — Payments: $41,045
Dr. Venee Tubman, M.d, M.D
Pediatric Hematology-Oncology — Payments: $32,728
Youngna Lee-Kim, Md, MD
Pediatric Hematology-Oncology — Payments: $29,576